FDA restricts Covid vaccine over safety issues — Analysis

“After conducting an updated analysis, evaluation and investigation of reported cases, the FDA has determined that the risk of thrombosis with thrombocytopenia syndrome (TTS)… warrants limiting the authorized use of the vaccine,”It was referring to blood-clotting disorder. The symptoms usually appear in the spring, it said. “approximately one to two weeks”Once the jab has taken place.

According to the FDA, individuals under 18 will be prohibited from receiving the shot. And even for adults, the J&J vaccine is now recommended only to those “for whom other authorized or approved Covid-19 vaccines are not accessible or clinically appropriate,”or would be prevented from receiving an immunization.

While the director of the FDA’s Center for Biologics Evaluation and Research, Peter Marks, argued the vaccine “still has a role in the current pandemic response”He spoke in the USA and worldwide. “the risk of TTS”The agency was forced to limit its usage among Americans.

The regulator’s latest decision is not the first setback for the J&J jab, whose rollout was placed on a brief pause in April 2021 following several blood-clotting cases. While the FDA reapproved the shot after a little more than a week, an advisory body at the Center for Disease Control and Prevention (CDC) later recommended other vaccines over Johnson & Johnson’s for all American adults after a review of effectiveness and safety data.